



MDwise PDL Changes April 2008 DUR Board Presentation

Additions to PDL with NO Clinical Edits

Cetirizine tablet, liquid, chewable
 MIRAPEX
 Terbinafine Tablet
 ELMIRON
 ESTRACE VAGINAL CREAM
 VAGIFEM VAGINAL TABLET
 INTELENCE

Additions to PDL with Clinical Edits

Product	Rationale
NA	NA

Changes to or Additions of Clinical Edits

Product	Rationale
PULMICORT RESPULE	Current Age edit for children under 4 years. Proposing QLL for 0.25mg amp = 1/day; QLL for 0.5mg and 1mg amps = 2/day
Fexofenadine products (except ODT)	Currently ST edit requiring 1 claim for loratadine in past 13 months. Proposing a change to the ST edit requiring evidence of 2 week trials of both loratadine and cetirizine products
Fluconazole products	Propose removing ST edit for Diflucan products and adding QLL for 50mg and 100mg tablets = 1/day; adding QLL for 200mg tablet = 2/day; adding QLL for 150mg tablet = 2/month; and adding QLL for 10mg/ml and 40mg/ml suspension = 35 ml/month

Remove from PDL

Product	Rationale
ALLEGRA	PDL options include loratadine and cetirizine products as first line agents.
Fexofenadine ODT	PDL options include loratadine and cetirizine products as first line agents.